* PathoGenesis Corp., of Seattle, completed two double-blindplacebo-controlled Phase III trials of TOBI (tobramycin forinhalation) for treating chronic lung infections in cystic fibrosispatients. The company said it expects to release results in the firstquarter of 1997 and file a new drug application by the end of thesecond quarter.
* Pharmacopeia Inc., of Princeton, N.J., said it reached a cashmilestone in its collaboration with Schering-Plough Corp., ofMadison, N.J., which will begin work on a lead compound identifiedfrom a Pharmacopeia library. The collaboration, in the areas ofcancer and asthma, was extended for an additional year.
* The Immune Response Corp., of Carlsbad, Calif., agreed todevelop and distribute its AIDS vaccine Remune in South andCentral America with Viru-Tech Ltd. Privately held Viru-Techpurchased $3 million of Immune Response stock at $12.77 per shareand will pay for any clinical trials.
* Vivus Inc., of Menlo Park, Calif., received an approvable letterfrom the FDA for the use of MUSE (alprostadil) in treatingimpotence.
(c) 1997 American Health Consultants. All rights reserved.